Huons Co., Ltd. (KOSDAQ:243070)

Market Cap	333.24B +17.3%
Revenue (ttm)	602.21B +2.3%
Net Income	35.75B +0.6%
EPS	2,985.83 +5.8%
Shares Out	11.65M
PE Ratio	9.58
Forward PE	n/a
Dividend	920.00 (3.22%)
Ex-Dividend Date	Apr 2, 2026

Volume	35,160
Average Volume	27,862
Open	28,700
Previous Close	28,750
Day's Range	28,300 - 29,000
52-Week Range	23,100 - 32,200
Beta	0.04
RSI	56.89
Earnings Date	Feb 12, 2026

About Huons

Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, anti-coagulant, antiviral, central nervous system, antibiotic, well-being, urogenital system, and other chemotherapeutic products; and injection products, such as anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1965
• Employees: 912
• Stock Exchange: KOSDAQ
• Ticker Symbol: 243070

Financial Performance

In 2024, Huons's revenue was 590.23 billion, an increase of 6.92% compared to the previous year's 552.01 billion. Earnings were 29.45 billion, a decrease of -41.64%.